BackBioline Rx Overview

Bioline Rx Long Term Debt

Bioline Rx's long-term debt is $4.3M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$4.34M
↓ 49.66% YoYΔ $-4.28M vs prior year quarter

Peer average

Loading

Bioline Rx Long Term Debt History

Loading

Bioline Rx vs. peers: Long Term Debt Comparison

Loading

Bioline Rx Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bioline Rx (BLRX) FAQ

As of the most recent data (March 2026), BLRX shows a long-term debt of $4.3M. That compares with $8.6M in the prior-year period — down 49.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLRX's long-term debt is now $4.3M (was $8.6M) — a 49.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bioline Rx is outperforming or lagging.

Tracking BLRX's long-term debt over time shows whether Bioline Rx is scaling, shrinking, or reshaping that part of the business. The current reading is $4.3M That compares with $8.6M in the prior-year period — down 49.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Bioline Rx's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $4.3M) with ownership activity and broader fundamentals.

Bioline Rx's long-term debt is $4.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.